Found charges a recurring plan fee that bundles clinical care and, on some plans, the medication itself. Brand-name GLP-1 drugs are billed separately. Labs are separate where they apply. The advertised entry rates require paying twelve months up front, and the month-to-month equivalents published alongside them are considerably higher.
All figures below come from Found’s own plans and pricing page and offer terms as published in July 2026. Prices in this category move, so the arithmetic matters more than any individual number.
The two rate cards
Found advertises its GLP-1 program from $99 per month with insurance and $169 per month cash-pay. The footnote states that pricing is based on twelve-month plans paid up front, and that monthly plans start at $199 per month with insurance and $289 per month cash-pay. So there are effectively two rate cards, and the one on the billboard is the prepaid one.
Found’s offer terms describe plan pricing as billed every four weeks on a 28-day cycle. That produces thirteen billing events across a calendar year rather than twelve, which is worth building into any annual estimate rather than discovering later.
Three plans with different inclusions
The offer terms set out three plan types, and the difference between them is entirely about what the fee covers.
| Plan | Medication included in the fee | Billed separately | Best suited to |
|---|---|---|---|
| Compounded GLP-1 | Compounded semaglutide or tirzepatide | Labs where applicable, any brand drug | Cash payers who accept a compounded preparation |
| Generics, oral non-GLP-1 | Certain generic oral medications | All GLP-1 medication, labs | People starting with non-injectable options |
| Branded GLP-1 | None; prescribing and support only | The entire drug cost, labs | People with coverage or manufacturer channel access |
On the branded plan, Found’s terms state that medication may be filled through a pharmacy of the member’s choice, through insurance, or where eligible through the manufacturers’ own self-pay channels. Its pricing page lists indicative brand costs of roughly $1,100 a month for Ozempic and Mounjaro, and from about $650 a month for Wegovy and Zepbound. Those are drug costs sitting on top of the plan fee, not instead of it.
Those brand figures are part of why the field looks so different depending on where a shopper starts. LillyDirect and NovoCare sell the manufacturers’ own branded drugs at set cash prices, Ro and Hims and Hers pair prescribing with fulfillment, and providers such as HealthRX post their GLP-1 medication pricing per strength so the yearly figure can be worked out before an account exists. The plan fee on its own rarely settles which provider is cheaper.
Where insurance does and does not help
The insurance rate is lower than the cash rate, and it is not the whole story. Found’s payment and billing consent states that the subscription fee is not a covered benefit under any health plan and is treated as a non-covered service, so the member is responsible for it in full. The same document states that charges for compounded GLP-1 medications are also non-covered, and asks members not to submit them to a plan.
On top of the plan fee, insurance members pay copays, coinsurance, or deductible amounts as their plan dictates. Found’s pricing FAQ describes a typical copay of around $30, with the caveat that the actual amount depends on the plan and deductible status. Found also states that its insurance plans are not available to people with government coverage such as Medicare, Medicaid, TriCare or MediCal.
The result is that insurance shifts the cost of the clinical visit but leaves the membership and any compounded drug outside coverage entirely. Anyone modeling cost should treat those as fixed cash outlays regardless of their plan.
Labs, shipping, and the pieces that appear later
Found’s plan descriptions note that labs, where applicable, are not included in the plan price. Lab work is common in metabolic care, so it belongs in a first-year budget even if it does not appear at checkout. Shipping of compounded medication is generally handled inside the plan on the compounded tier, since the drug is bundled, but the fulfillment schedule is set by the compounding pharmacy rather than by the platform.
Promotional discounts are the other moving part. Found’s offer terms describe a discount of $100 or more per month on prepaid annual compounded plans compared with paying monthly, discounts at checkout on brand-supporting plans, and exclusion of Med Kit plans from all discounts. Its terms also state that discount offers requiring payment are non-refundable unless stated otherwise in writing.
Comparing this against other cash-pay programs is only meaningful at the strength you expect to reach, since compounded pricing usually scales with dose. FormBlends is among the physician-supervised providers that publish compounded pricing per strength up front, which is the format that makes a genuine like-for-like annual comparison possible.
What compounded pricing does not buy
Compounded semaglutide and tirzepatide are not FDA-approved products. The agency has not reviewed those specific preparations for safety, effectiveness, or manufacturing quality, and Found’s own footnotes say as much. Published pharmacy literature notes that compounded incretin products can use formulations that differ from the approved reference product, with efficacy and safety largely unstudied, and clinical opinion pieces from pharmacy practice groups have flagged the documentation and monitoring gaps that follow.
That is a fact about the product category rather than about any one seller, and it is the main reason a lower monthly figure on a compounded plan is not straightforwardly a better deal than a higher one on an approved brand drug.
One naming point worth clearing up
Found lists Foundayo among the medications it can prescribe. Foundayo is Eli Lilly’s brand name for orforglipron, an oral medication approved in April 2026 under application NDA 220934. Despite the similar names it is not a Found product, and Found’s site states that the company is not affiliated with or endorsed by Eli Lilly. Confusing the two would lead to real pricing errors, since one is a plan and the other is a drug.
Frequently asked questions
Is the plan fee the total monthly cost?
On the compounded tier it usually is, because the medication is bundled. On the branded tier it is not, since the drug is billed separately and typically costs several times the plan fee. Reading which tier a quoted price belongs to is the first step in any comparison across providers.
Why do the advertised and checkout prices differ?
The lowest advertised rates apply to twelve-month plans paid up front. Choosing month-to-month billing moves the price to a higher published tier. This is disclosed in the footnote under the headline rate, and it is the single most common source of surprise at checkout across this whole category.
Do prices rise as the dose increases?
Compounded pricing commonly scales with strength, so a figure quoted at a starting dose can understate month six. Ask for the price at the highest strength you might reach before committing to any annual plan, since that is the number that determines the real cost of a year of treatment.
Can a health savings account cover any of it?
Found markets the program as HSA and FSA eligible, while its terms note that subscription fees may not be submissible for coverage under insurance or similar third-party payment plans. Those are different mechanisms, and the safe move is to confirm eligibility of each line item with the account administrator before assuming it qualifies.
By
